Therapy

2019 – ICHNO – Phase I/II NBTXR3 in HNSCC

Clinical Data NBTXR3, Congress Abstracts, Head & Neck

Hafnium oxide nanoparticles, NBTXR3, were developed to augment tumor-localized high energy deposit once activated by ionizing radiation such as Intensity Modulated Radiation Therapy (IMRT) and thus to increase tumor cell death compared to the same dose of radiation. NBTXR3 is characterized by a single intratumoral (IT) administration and fits into standard radiotherapy schedule with no change in patient’s care pathway, treatment protocol or equipment. […]

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.